Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CinnaGen Pertuzumab versus Perjeta in neoadjuvant HER2-positive breast cancer
IRCT20150303021315N11Phase 3Completed
- Sponsor
- CinnaGen
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of pertuzumab in breast cancer (2 arms), sponsored by CinnaGen. Primary endpoint: pathologic complete response. Started Aug 2018; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20150303021315N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150303021315N11.